Dl. Vesely et al., ATRIAL NATRIURETIC PEPTIDES AND CYCLIC GUANOSINE-MONOPHOSPHATE METABOLISM, The American journal of the medical sciences, 310(4), 1995, pp. 143-149
Atrial natriuretic factor (ANF), consisting of amino acids 99-126 of t
he 126 amino acid ANF prohormone, increases cyclic guanosine monophosp
hate (GMP) (thought to be the mediator of its physiologic effects) in
plasma and urine of human subjects. Long-acting natriuretic peptide, v
essel dilator, and kaliuretic peptide, consisting of amino acid 1-30,
31-67, and 79-98, respectively, of this same prohormone have natriuret
ic, diuretic, kaliuretic, and blood pressure lowering properties in hu
mans. These three new peptide hormones increase cyclic GMP in vitro bu
t were never investigated to determine whether they also cause extrusi
on of cyclic GMP from cells, resulting in an increase of cyclic GMP in
plasma and/or urine, Infusion of each of these peptide hormones at th
eir 100 ng/kg body weight/min concentrations for 60 minutes into healt
hy humans resulted in a sevenfold increase in cyclic GMP in plasma and
urine secondary to ANF, but no significant increase secondary to the
other atrial peptide hormones. Based on the current data, ANF has a un
ique effect on the metabolism of cyclic GMP, causing it to be extruded
from the cell, whereas the other three atrial peptides represent the
more classical metabolism of cyclic GMP via cyclic GMP phophodiesteras
es.